Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

@article{Meyers2004NeurocognitiveFA,
  title={Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.},
  author={Christina A. Meyers and Jennifer A Smith and Andrea Bezjak and Minesh P. Mehta and James E Liebmann and Tim M Illidge and Ian Kunkler and J M Caudrelier and Peter Eisenberg and Jacobus H. Meerwaldt and Ross Siemers and Christian Carrie and Laurie E. Gaspar and Walter P. Curran and S C Phan and Richard L. Miller and Markus Frederic Renschler},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 1},
  pages={157-65}
}
PURPOSE To report the neurocognitive findings in a phase III randomized trial evaluating survival and neurologic and neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain radiation therapy (WBRT) with or without motexafin gadolinium (MGd). PATIENTS AND METHODS Patients were randomly assigned to receive WBRT 30 Gy in 10 fractions with or without MGd 5 mg/kg/d. Monthly neurocognitive testing for memory, executive function, and fine motor skill was… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS